James F. Oliviero III
2017
In 2017, James F. Oliviero III earned a total compensation of $645K as Chief Executive Officer and President at Checkpoint Therapeutics, a 73% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $215,000 |
|---|---|
| Salary | $430,000 |
| Total | $645,000 |
Oliviero received $430K in salary, accounting for 67% of the total pay in 2017.
Oliviero also received $215K in non-equity incentive plan.
Rankings
In 2017, James F. Oliviero III's compensation ranked 10,934th out of 14,666 executives tracked by ExecPay. In other words, Oliviero earned more than 25.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,934 out of 14,666 | 25th |
Division Manufacturing | 4,269 out of 5,772 | 26th |
Major group Chemicals And Allied Products | 1,536 out of 2,075 | 26th |
Industry group Drugs | 1,259 out of 1,731 | 27th |
Industry Pharmaceutical Preparations | 981 out of 1,333 | 26th |
Source: SEC filing on April 30, 2018.
Oliviero's colleagues
We found one more compensation record of an executive who worked with James F. Oliviero III at Checkpoint Therapeutics in 2017.
2017
William Gray
Checkpoint Therapeutics
Vice President, Finance and Accounting
News
Checkpoint Therapeutics CEO James Oliviero's 2023 pay slips 20% to $1.6M
April 2, 2024
Checkpoint Therapeutics CEO James Oliviero's 2022 pay slips 11% to $2M
May 1, 2023
Checkpoint Therapeutics CEO James Oliviero's 2021 pay stays at $2.3M
April 29, 2022
Checkpoint Therapeutics CEO James Oliviero's 2020 pay slips 1% to $2.3M
April 30, 2021
Checkpoint Therapeutics CEO James Oliviero's 2019 pay rises 8% to $2.3M
April 24, 2020
Checkpoint Therapeutics CEO James Oliviero's 2018 pay jumps 230% to $2.1M
April 30, 2019